Articles from Apollo Technology Capital Corporation

MediPharm Labs Refuses to Answer Direct Questions Regarding Credible Securities Fraud Allegations Says Apollo Capital

Demands Management’s Board Nominees John Medland and Emily Jameson Withdraw Immediately or Face Public Complicity in Ongoing Alleged Systemic Violations of Securities Laws

By Apollo Technology Capital Corporation · Via GlobeNewswire · May 30, 2025

Alleged Securities Fraud at MediPharm Labs Says Apollo Capital

Multiple Highly Credible Sources Reveal Disturbing Evidence of Alleged Systemic Violations of Securities Laws at MediPharm Labs; Immediate Regulatory Action Demanded

By Apollo Technology Capital Corporation · Via GlobeNewswire · May 29, 2025

Apollo Capital Calls Out MediPharm Chairman Chris Taves (Managing Director, BMO Capital Markets) for Failure to Properly Communicate to Shareholders Details of David Pidduck’s Past as CEO and VP of Marketing for OxyContin® Manufacturer Purdue Pharma

Opioid-Pusher Pidduck, Chairman Chris Taves and the Current MediPharm Board Have Presided Over $1 Billion in Shareholder Value Destruction while funneling $5,587,059 of the Shareholders’ Money Directly into Pidduck’s Pocket

By Apollo Technology Capital Corporation · Via GlobeNewswire · May 27, 2025

Apollo Capital Comments on MediPharm Labs’ Failure to Respond to Reasonable Offer to Ensure Fair, Lawful and Transparent 2025 Annual Meeting

MediPharm Labs Board Continues to Obstruct the Appointment and Oversight of an Independent Chair

By Apollo Technology Capital Corporation · Via GlobeNewswire · May 23, 2025

Apollo Capital Issues a With Prejudice Offer to MediPharm Labs and Its Board of Directors to Ensure Shareholder Rights Are Protected at the 2025 Annual Meeting

Believes the Board Continues to Take Oppressive Actions Which Fundamentally Disregard the Rights and Interests of Shareholders

By Apollo Technology Capital Corporation · Via GlobeNewswire · May 21, 2025